Inhibition of NAD(P)H oxidase attenuates aggregation of platelets from high-risk cardiac patients with aspirin resistance

Pharmacological Reports

Volumn 59, Issue 4, 2007, Pages 428-436

  Stef, Gyorgyi ^a   Csiszar, Anna ^b   Xiangmin, Zhao ^b   Ferdinandy, Peter ^c   Ungvari, Zoltan ^b   Veress, Gabor ^a  

^a State Hospital for Cardiology Hungary   (Hungary)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Coronary artery disease; Myocardial infarction; NADPH oxidase; Oxidative stress; Thrombocyte; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ANGIOTENSIN RECEPTOR ANTAGONIST; APOCYNIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENYLIODONIUM SALT; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LUCIGENIN; NITRATE; OXIDOREDUCTASE; OXYGEN; PROTEIN P67PHOX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CELL ISOLATION; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBUNIT; FEMALE; FUNCTION TEST; HEART DISEASE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LONG TERM CARE; MALE; OXIDATIVE STRESS; PROTEIN EXPRESSION; STABLE ANGINA PECTORIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; UNSTABLE ANGINA PECTORIS; WESTERN BLOTTING;

EID: 35048860281     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Altman R, Luciardi HL, Muntaner J, Herrera RN: The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb J, 2004, 2, 1.
2. Antithrombotic-Trialists'-Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002, 324, 71-86.
3. Begonja AJ, Gambaryan S, Geiger J, Aktas B, Pozgajova M, Nieswandt B, Walter U: Platelet NAD(P)H-oxidase-generated ROS production regulates alphaIIbbeta.3-integrin activation independeht of the NO/cGMP pathway. Blood, 2005, 106, 2757-2760.
4. Begonja AJ, Teichmann L, Geiger J, Gambaryan S, Walter U: Platelet regulation by NO/cGMP signaling and NAD(P)H oxidase-generated ROS. Blood Cells Mol Dis, 2006, 36, 166-170.
5. +-ATPase activity in leptin-treated rats. Pharmacol Rep. 2005, 57, 219-228.
6. Borutaite V. Hope H, Brown GC: Arachidonate and NADPH oxidase synergise with iNOS to induce death in macrophages: mechanisms of inflammatory degeneration. Pharmacol Rep, 2006, 58, Suppl, 96-102.
7. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. New Engl J Med, 2001, 345, 1583-1592.
8. Celestini A, Pulcinelli FM, Pignatelli P, Lenti L, Frati G, Gazzaniga PP, Violi F: Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets. Haematologica, 2002, 87, 420-426.
9. Cheung MC, Zhao XQ, Chait A, Albers JJ, Brown BG: Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol, 2001, 21, 1320-1326.
10. Chlopicki S, Olszanecki R, Janiszewski M, Laurindo FR, Panz T, Miedzobrodzki J: Functional role of NADPH oxidase in activation of platelets. Antioxid Redox Signal, 2004, 6, 691-698.
11. Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Di Gregorio D, Bucciarelli T, Davi G et al.: Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation, 2000, 102, 1007-1013.
12. Clutton P, Miermont A, Freedman JE: Regulation of endogenous reactive oxygen species in platelets can reverse aggregation. Arterioscler Thromb Vasc Biol, 2004, 24, 187-192.
13. Csiszar A, Ahmad M, Smith KE, Labinskyy N, Gao Q, Kaley G, Edwards JG, Wolin MS, Ungvari Z: Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype. Am J Pathol, 2006, 168, 629-638.
14. Csiszar A, Stef G, Pacher P, Ungvari Z: Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandins Leukot Essent Fatty Acids, 2002, 66, 557-558.
15. Csiszar A, Ungvari Z, Edwards JG, Kaminski PM, Wolin MS, Koller A, Kaley G: Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res, 2002, 90, 1159-1166.
16. Csiszar A, Ungvari Z, Koller A, Edwards JG, Kaley G: Aging-induced proinflammatory shift in cytokine expression profile in rat coronary arteries. FASEB J, 2003, 17, 1183-1185.
17. De Biase L, Pignatelli P, Lenti L, Tocci G, Piccioni F, Riondino S, Pulcinelli FM et al.: Enhanced TNF alpha and oxidative stress in patients with heart failure: effect of TNF alpha on platelet O2- production. Thromb Haemost, 2003, 90, 317-325.
18. De Gaetano G, Cerletti C: Aspirin resistance: a revival of platelet aggregation tests? J Thromb Haemost, 2003, 1, 9, 2048-2050.
19. Engels F, Renirie BF, Hart BA, Labadie RP, Nijkamp FP: Effects of apocynin, a drug isolated from the roots of Picrorhiza kurroa, on arachidonic acid metabolism. FEBS Lett, 1992, 305, 254-256.
20. Frelinger AL, 3rd, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD: Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation, 2006, 113, 25, 2888-2896.
21. Friend M, Vucenik I, Miller M: Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ, 2003, 326, 82-83.
22. Germano G, Sanguigni V, Pignatelli P, Caccese D, Lenti L, Ragazzo M, Lauro R, Violi F: Enhanced platelet release of superoxide anion in systemic hypertension: role of AT1 receptors. J Hypertens, 2004, 22, 1151-1156.
23. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res, 2000, 86, 494-501.
24. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H: Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol, 2003, 250, 63-66.
25. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ; Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol, 2001, 88, 230-235.
26. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol, 2003, 41, 961-965.
27. Hankey GJ, Eikelboom JW: Aspirin resistance. Lancet, 2006, 367, 606-617.
28. Minuz P, Fava C, Lechi A: Lipid peroxidation, isoprostanes and vascular damage. Pharmacol Rep, 2006, 58, Suppl, 57-68.
29. MRC/BHF Heart-Protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 23-33.
30. Orosz Z. Csiszar A, Labinskyy N, Smith K, Kaminski PM, Ferdinandy P, Wolin MS et al.: Cigarette smoke-induced pro-inflammatory alterations in the endothelial phenotype: role of NAD(P)H oxidase activation. Am J Physiol Heart Circ Physiol, 2007, 292, H130-139.
31. Pignatelli P, De Biase L, Lenti L, Tocci G, Brunelli A, Cangemi R, Riondino S et al.: Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure. Blood, 2005, 106, 1992-1994.
32. Pignatelli P. Di Santo S, Buchetti B, Sanguigni V, Brunelli A, Violi F: Polyphenols enhance platelet nitric oxide by inhibiting protein kinase C-dependent NADPH oxidase activation: effect on platelet recruitment. FASEB J, 2006, 20, 1082-1089.
33. Pignatelli P, Sanguigni V, Lenti L, Ferro D, Finocchi A, Rossi P, Violi F: gp91phox-dependent expression of platelet CD40 ligand. Circulation, 2004, 110, 13267-1329.
34. Plumb RD, EI-Sherbeeny NA, Dixon LJ, Hughes SM, Devine AB, Leahey WJ, McVeigh GE: NAD(P)H-dependent superoxide production in platelets: the role of angiotensin II and protein kinase C. Clin Biochem, 2005, 38, 607-613.
35. Pulcinelli FM, Riondino S, Celestini A, Pignatelli P, Trifiro E, Di Renzo L, Violi F: Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Haemost, 2005, 3, 2784-2789.
36. Rozalski M, Boncler M, Luzak B. Watala C: Genetic factors underlying differential blood platelet sensitivity to inhibitors. Pharmacol Rep, 2005, 57, 1-13.
37. Salvemini D, Radziszewski W, Mollace V, Moore A, Willoughby D, Vane J: Diphenylene iodonium, an inhibitor of free radical formation, inhibits platelet aggregation. Eur J Pharmacol, 1991, 199, 15-18.
38. Seno T, Inoue N, Gao D, Okuda M, Sumi Y, Matsui K, Yamada S. Hirata KI et al.: Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb Res, 2001, 103, 399-409.
39. Stef G, Csiszar A, Lerea K, Ungvari Z, Veress G: Resveratrol Inhibits Aggregation of Platelets from High-risk Cardiac Patients with Aspirin Resistance. J Cardiovasc Pharmacol, 2006, 48, 1-5.
40. Stokes KY, Calahan L, Russell JM, Gurwara S, Granger DN: Role of platelets in hypercholesterolemia-induced leukocyte recruitment and arteriolar dysfunction. Microcirculation (New York), 2006, 13, 377-388.
41. Szczeklik A, Musial J, Undas A, Sanak M, Nizankowski R: Aspirin resistance. Pharmacol Rep, 2005, 57, Suppl, 33-41.
42. Tailor A, Granger DN: Hypercholesterolemia promotes P-selectin-dependent platelet-endothelial cell adhesion in postcapillary venules. Arterioscler Thromb Vasc Biol, 2003, 23, 675-680.
43. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G, Koller A: Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol, 2003, 23, 418-424.
44. Ungvari Z, Csiszar A, Kaminski PM, Wolin MS, Koller A: Chronic high pressure-induced arterial oxidative stress: Involvement of protein kinase C-dependent NAD(P)H oxidase and local renin-angiotensin system. Am J Pathol, 2004, 165, 219-226.
45. 2 activity in isolated arterioles and platelets of rats with hyperhomocysteinemia. Arterioscler Thromb Vasc Biol, 2000, 20, 1203-1208.
46. Watala C, Boncler M, Gresner P: Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep, 2005, 57, Suppl, 42-58.
47. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New Engl J Med, 2000, 342, 154-160.